Generic Neuraceq Availability
NEURACEQ (florbetaben f-18 - solution;intravenous)
Manufacturer: PIRAMAL IMAGING
Approval date: March 19, 2014
Strength(s): 30ML (1.4-135mCi/ML) [RLD]
Has a generic version of Neuraceq been approved?
No. There is currently no therapeutically equivalent version of Neuraceq available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Neuraceq. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Stilbene derivatives and their use for binding and imaging amyloid plaques
Issued: October 5, 2010
Inventor(s): Kung; Hank F. & Kung; Mei-Ping & Zhuang; Zhi-Ping
Assignee(s): The Trustees of the University of Pennsylvania
This invention relates to a method of imaging amyloid deposits and to labeled compounds, and methods of making labeled compounds useful in imaging amyloid deposits. This invention also relates to compounds, and methods of making compounds for inhibiting the aggregation of amyloid proteins to form amyloid deposits, and a method of delivering a therapeutic agent to amyloid deposits.Patent expiration dates:
- March 18, 2029✓✓✓
- March 18, 2029
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
- Exclusivity expiration dates:
- March 21, 2019 - NEW CHEMICAL ENTITY
More about Neuraceq (florbetaben f-18)
- Side Effects
- During Pregnancy
- Dosage Information
- Support Group
- 0 Reviews – Add your own review/rating
Related treatment guides
|Drug Patent||A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.|
|Drug Exclusivity||Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.|
|RLD||A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.|